These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24095214)

  • 1. [Resistance to acenocoumarol revealing a missense mutation of the vitamin K epoxyde reductase VKORC1: a case report].
    Mboup MC; Dia K; Ba DM; Fall PD
    Ann Cardiol Angeiol (Paris); 2015 Feb; 64(1):59-61. PubMed ID: 24095214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.
    Stepien E; Branicka A; Ciesla-Dul M; Undas A
    J Appl Genet; 2009; 50(4):399-403. PubMed ID: 19875892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol.
    Sehgal T; Hira JK; Ahluwalia J; Das R; Vijayvergiya R; Rana SS; Varma N
    Drug Discov Ther; 2015 Dec; 9(6):404-10. PubMed ID: 26781925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].
    Loriot MA; Beaune P
    Rev Med Interne; 2006 Dec; 27(12):979-82. PubMed ID: 17070618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.
    Harrington DJ; Underwood S; Morse C; Shearer MJ; Tuddenham EG; Mumford AD
    Thromb Haemost; 2005 Jan; 93(1):23-6. PubMed ID: 15630486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new VKORC1 allelic variant (p.Trp59Arg) in a patient with partial resistance to acenocoumarol and phenprocoumon.
    Wilms EB; Touw DJ; Conemans JM; Veldkamp R; Hermans M
    J Thromb Haemost; 2008 Jul; 6(7):1224-6. PubMed ID: 18419745
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetic causes of resistance to vitamin K antagonists in Polish patients: a novel p.Ile123Met mutation in VKORC1 gene.
    Wzorek J; Wypasek E; Awsiuk M; Potaczek DP; Undas A
    Blood Coagul Fibrinolysis; 2018 Jul; 29(5):429-434. PubMed ID: 29794812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.
    Smires FZ; Habbal R; Moreau C; Assaidi A; Loriot MA; Nadifi S
    Pathol Biol (Paris); 2013 Jun; 61(3):88-92. PubMed ID: 23201087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
    Wolkanin-Bartnik J; Pogorzelska H; Szperl M; Bartnik A; Koziarek J; Bilinska ZT
    Pharmacogenet Genomics; 2013 Nov; 23(11):611-8. PubMed ID: 24108193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of protein disulfide isomerase enhances vitamin K epoxide reductase activity.
    Chetot T; Benoit E; Lambert V; Lattard V
    Biochem Cell Biol; 2022 Apr; 100(2):152-161. PubMed ID: 35007172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Resistance to coumarin derivatives due to mutated vitamin-K enzyme].
    Hermans MH; Poodt J; van Geest-Daalderop JH; Péquériaux NC; Conemans JM
    Ned Tijdschr Geneeskd; 2009; 153():A691. PubMed ID: 19857286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.
    Teichert M; van Schaik RH; Hofman A; Uitterlinden AG; de Smet PA; Stricker BH; Visser LE
    Clin Pharmacol Ther; 2009 Apr; 85(4):379-86. PubMed ID: 19225451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Partial resistance to acenocoumarol and phenprocoumon caused by enzyme polymorphism].
    Wilms EB; Veldkamp RF; van Meegen E; Touw DJ
    Ned Tijdschr Geneeskd; 2006 Sep; 150(38):2095-8. PubMed ID: 17036862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
    Markatos CN; Grouzi E; Politou M; Gialeraki A; Merkouri E; Panagou I; Spiliotopoulou I; Travlou A
    Pharmacogenomics; 2008 Nov; 9(11):1631-8. PubMed ID: 19018719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling.
    Lewis BC; Nair PC; Heran SS; Somogyi AA; Bowden JJ; Doogue MP; Miners JO
    Pharmacogenet Genomics; 2016 Jan; 26(1):44-50. PubMed ID: 26513304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Partial resistance to acenocoumarol and phenprocoumon caused by enzyme polymorphism].
    Niermeijer MF
    Ned Tijdschr Geneeskd; 2006 Dec; 150(51):2839; author reply 2839-40. PubMed ID: 17216734
    [No Abstract]   [Full Text] [Related]  

  • 17. Exacerbation of hereditary warfarin resistance by azathioprine.
    Pushpakom SP; Gambhir N; Latif A; Hadfield KD; Campbell S; Newman WG
    Clin Appl Thromb Hemost; 2011 Jun; 17(3):293-6. PubMed ID: 20211925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay.
    Fregin A; Czogalla KJ; Gansler J; Rost S; Taverna M; Watzka M; Bevans CG; Müller CR; Oldenburg J
    J Thromb Haemost; 2013 May; 11(5):872-80. PubMed ID: 23452238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
    van Schie RM; Babajeff AM; Schalekamp T; Wessels JA; le Cessie S; de Boer A; van der Meer FJ; van Meegen E; Verhoef TI; Rosendaal FR; Maitland-van der Zee AH;
    J Thromb Haemost; 2012 May; 10(5):767-72. PubMed ID: 22409277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance.
    Bodin L; Horellou MH; Flaujac C; Loriot MA; Samama MM
    J Thromb Haemost; 2005 Jul; 3(7):1533-5. PubMed ID: 15978113
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.